Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors’
SAN DIEGO Contineum Therapeutics, Inc. (Nasdaq: CTNM), a forward-thinking clinical stage biopharmaceutical company, has further solidified its executive leadership through the strategic addition of Sarah Boyce to its Board of Directors. Underlying this significant appointment is Contineum Therapeutics’ commitment to revolutionizing the treatment landscape within the realms of neuroscience, inflammation, and immunology (NI&I) through the development of cutting-edge, oral small molecule therapies.
Sarah Boyce, who currently serves as the President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), brings a wealth of experience and a proven track record in biopharmaceutical innovation. Her deep expertise in the biotechnology sector, coupled with strategic leadership acumen, aligns seamlessly with Contineum Therapeutics’ ambitious vision of addressing unmet medical needs in the NI&I therapeutic areas.
We are thrilled to welcome Sarah to our Board of Directors, said Dr. Jane Andrews, CEO of Contineum Therapeutics. Her distinguished background in biotechnology and her leadership at Avidity Biosciences highlight her capability to provide invaluable insights and guidance as we continue to advance our research and development initiatives aimed at transforming patient care.
At Avidity Biosciences, Boyce has been instrumental in advancing the company’s novel approach to RNA therapeutics. Her leadership has been pivotal in driving the company’s success in developing therapies that address previously untreatable conditions, a mission that resonates closely with Contineum Therapeutics’ goal of pioneering treatments for complex diseases.
Boyce’s appointment to the Board is expected to enhance Contineum’s strategic direction and operational execution, particularly as the company progresses its clinical programs and scales its innovative platforms. Her expansive network and deep understanding of the regulatory landscape will be instrumental in navigating the intricacies of biopharmaceutical development and commercialization.
I am honored to join the Board of Directors at Contineum Therapeutics, said Sarah Boyce. I look forward to contributing to Contineum’s mission of developing novel therapies that have the potential to significantly improve patient outcomes in neuroscience, inflammation, and immunology.
The addition of Boyce underscores Contineum Therapeutics’ dedication to expanding its leadership with seasoned experts who can guide the company through crucial phases of clinical development and market introduction. As Contineum continues to chart a path toward clinical excellence and groundbreaking therapeutic solutions, Boyce’s expertise and strategic vision will undoubtedly be a cornerstone of its future successes.
In summary, Contineum Therapeutics’ announcement of Sarah Boyce’s appointment epitomizes a crucial step in fortifying the company’s leadership team as it embarks on the next transformative phase of its journey. Her inclusion is poised to bring about meaningful advancements in Contineum’s pursuit of scientific innovation and therapeutic breakthroughs within the biopharmaceutical industry.
Comments